LBI Group

Life Science Business (LBI) is a Japanese biotechnology company specializing in regenerative medicine and cell therapy, with a primary focus on mesenchymal stem cell (MSC) technologies. The company develops proprietary cell-based products for high-unmet-need conditions, including acute graft-versus-host disease (aGvHD) and liver cirrhosis. Beyond its internal pipeline, LBI operates as a specialized contract research and manufacturing organization (CRO/CMO), providing support for cell processing and clinical development to external partners. By leveraging its expertise in cell culture and quality control, LBI aims to accelerate the commercialization of regenerative therapies in the Asian market and beyond.